How should follow-up and treatment-center claims be assessed?
What care should remain in view?
Any discussion of an intervention for opioid use disorder should keep evidence-based treatment in view. Medications for opioid use disorder, including buprenorphine, methadone, and naltrexone in appropriate circumstances, along with counseling and recovery supports, remain central topics for discussion with qualified clinicians. SAMHSA’s guidance on medications for substance use disorders explains the role of these treatments.
People comparing ibogaine treatment options in Mexico may want to ask how continuity of care, overdose prevention, medication transitions, and return-home planning are addressed. These questions also fit the broader safety context covered on the safety and risk guidance.
How should anecdotal reports be interpreted?
Anecdotes can communicate a person’s experience, but they cannot reliably answer how often an outcome occurs, who was excluded, what adverse events happened, or whether benefits lasted. Be especially cautious when a center presents only selected success stories, uses unclear outcome measures, or treats a vivid personal account as proof.
A directory such as a list of ibogaine clinics may identify places people are discussing, not validate their claims. For a broader orientation to the subject and its limits, return to the Moksha Circuit overview of ibogaine and fentanyl addiction; the site’s approach to independent information explains the importance of evidence before hype.
This FAQ is informational only. It does not assess eligibility, provide medical or legal advice, or endorse a clinic, treatment center, or intervention.
